Every 10-Q that Century Therapeutics, Inc. (IPSC) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow IPSC and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full IPSC filings page.
Century Therapeutics reported a larger net loss as collaboration revenue fell away but liquidity strengthened. For the quarter ended June 30, 2026, net loss was $34.6 million (six‑month loss $56.2 million) versus six‑month net income of $44.0 million a year earlier, when $109.2 million of Bristol‑Myers Squibb collaboration revenue was recognized.
Total assets were $287.0 million, including cash, cash equivalents and investments of $197.2 million. A January 2026 private placement raised about $126.4 million, increasing shares outstanding to 180.5 million. Management expects existing cash resources to fund operations into the first quarter of 2029.
Research and development and general and administrative expenses declined year over year, but results included an $11.1 million loss on a Philadelphia lease component termination. The company derecognized $3.8 million of contingent consideration after milestones expired and continues IND‑enabling work on lead programs CNTY‑813 and CNTY‑308.
Century Therapeutics, Inc. reported a net loss of $21.6 million for the three months ended March 31, 2026, compared with net income of $76.6 million a year earlier, when results included a large one-time collaboration revenue from Bristol-Myers Squibb.
Collaboration revenue was $0 this quarter versus $109.2 million in the prior-year period. Research and development expenses declined to $17.1 million from $26.6 million, and general and administrative expenses fell to $6.6 million from $8.4 million, reflecting cost controls and portfolio focus.
Cash, cash equivalents and investments totaled about $217.0 million, and management believes this will fund operations into the first quarter of 2029. During the quarter, the company closed a $126.4 million private placement, significantly increasing shares outstanding while supporting development of lead iPSC-derived cell therapy programs CNTY-813, CNTY-308 and CNTY-101.
Century Therapeutics (IPSC) filed its Q3 2025 10‑Q, reporting a quarterly net loss of $34,422 as collaboration revenue fell to zero following the Bristol‑Myers Squibb termination. For the nine months, the company posted net income of $9,591, driven by $109,164 of collaboration revenue recognized in Q1 when option rights expired.
Total assets were $244,717 versus $353,216 at year‑end, reflecting lower investments and lease assets. Cash, cash equivalents and investments were $132,748 as of September 30, 2025. Current liabilities declined to $22,026 from $129,782, primarily as deferred revenue was recognized. Stockholders’ equity rose to $176,348.
Q3 operating expenses were $36,124, including R&D $22,526, G&A $6,835, and a $6,763 impairment tied to lease strategy changes. The company executed lease modifications, recording a $1,395 gain and expects Seattle and Boston lease terminations by early 2026 with a new Watertown lease to commence thereafter. Management states it has adequate resources to operate for at least the next 12 months. As of November 1, 2025, common shares outstanding were 87,307,091.
Century Therapeutics (IPSC) reported operational updates reflecting continued development of its iPSC-derived cell therapy pipeline and recent acquisition activity. The company disclosed 86,322,071 shares outstanding at June 30, 2025 versus 85,836,429 at December 31, 2024. Century completed the acquisition of Clade, issuing 3,741,646 common shares at close and recording holdback shares of up to 793,687 subject to indemnification adjustments. Contingent consideration at closing included a fair-value amount of $2,600 plus a potential Clade milestone valued at $8,883, and a possible milestone payment of $10,000 payable in cash, shares, or combination.
The filing outlines program progress and capabilities including lead candidate CNTY-101, preclinical programs from Clade, and additional CAR-iT candidates (CNTY-308, CNTY-341) using the company’s Allo-Evasion™ and iPSC platforms. The company reported prior ATM sales of 4,084,502 shares for net proceeds of $17,829 in the six months ended June 30, 2024 and no ATM sales in the six months ended June 30, 2025. Quarter-over-quarter operating expense shifts include G&A of $7.8M versus $8.3M in the prior-year quarter and mixed R&D and facility cost changes driven by staff reductions, consolidation of lab operations, and completion of a manufacturing campaign under the FCDI collaboration.